Building CRISPR-Based Gene-Editing Platforms for Personalized Medicine: The Next Step in Interventional Genetics
Genes · 30.05.2026 · 17 (6) · 631
DOI: 10.3390/genes17060631 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 30.05.2026. Verfasst von Sebastian Hernandez Rodriguez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, University of Alberta, Edmonton, AB T6G 2H7, Canada. Hauptthemen laut MEDLINE: Precision Medicine, Gene Editing, CRISPR-Cas Systems, Genetic Therapy. Die Arbeit nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Recent advances in CRISPR technology have expanded beyond traditional double-strand break–based genome editing to include base editors and prime editors, enabling precise and programmable sequence modifications. This evolution marks a shift from conventional mutation correction toward platform-based therapeutic systems capable of targeting a broad spectrum of pathogenic variants. Such versatility holds promise for addressing a substantial proportion of known disease-causing mutations in rare monogenic disorders. This review discusses the technological progression of CRISPR systems, highlighting the principles, applications, and limitations of emerging editing modalities. We will explore their translation into personalized gene therapies, emphasizing delivery challenges, off-target safety, and the need for regulatory innovation. The paper will also introduce the concept of interventional genetics, an emerging medical framework linking genomic diagnosis directly to therapeutic intervention through adaptive gene-editing platforms. Finally, we will outline strategies for establishing unified, scalable, and regulatory-ready editing platforms that can accelerate the clinical implementation of individualized therapies for rare diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Genetics, University of Alberta, Edmonton, AB T6G 2H7, Canada.
ORCID-Profile: Toshifumi Yokota
Zitieren
APA
Rodriguez, S. H., & Yokota, T. (2026). Building CRISPR-Based Gene-Editing Platforms for Personalized Medicine: The Next Step in Interventional Genetics. Genes, 17(6), 631. https://doi.org/10.3390/genes17060631
Vancouver
Rodriguez SH, Yokota T. Building CRISPR-Based Gene-Editing Platforms for Personalized Medicine: The Next Step in Interventional Genetics. Genes. 2026;17(6):631. doi:10.3390/genes17060631
BibTeX
@article{Rodriguez2026,
author = {Rodriguez, Sebastian Hernandez and Yokota, Toshifumi},
title = {Building CRISPR-Based Gene-Editing Platforms for Personalized Medicine: The Next Step in Interventional Genetics},
journal = {Genes},
year = {2026},
volume = {17},
number = {6},
pages = {631},
doi = {10.3390/genes17060631}
}
EUVIMED